XML 41 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Research and development $ 33,656,000 $ 23,849,000
General and administrative 11,330,000 11,896,000
Total operating expenses 44,986,000 35,745,000
Loss from operations (44,986,000) (35,745,000)
Other (expense) income    
Change in fair value of warrant liabilities (3,886,000) (2,000)
Loss on issuance of pre-funded warrants (3,502,000) 0
Change in fair value of derivative liability 0 429,000
Gain on extinguishment of promissory notes payable 0 605,000
Gain on sale of equipment 3,000 0
Foreign exchange transaction gain 151,000 204,000
Interest income 777,000 373,000
Interest expense (455,000) (1,059,000)
Total other (expense) income, net (6,912,000) 550,000
Provision for income taxes 0 0
Net loss (51,898,000) (35,195,000)
Other comprehensive gain (loss):    
Foreign currency translation adjustment 22,000 (197,000)
Comprehensive loss $ (51,876,000) $ (35,392,000)
Net loss per common share, basic (in dollars per share) $ (4.25) $ (6.96)
Net loss per common share, diluted (in dollars per share) $ (4.25) $ (6.96)
Weighted average common shares outstanding, basic (in shares) 12,202,996 5,056,225
Weighted average common shares outstanding, diluted (in shares) 12,202,996 5,056,225